Future options of anti-angiogenic cancer therapy

被引：0

作者：

Yihai Cao ^{[1
,2
,3
]}

机构：

[1] Department of Microbiology,Tumor and Cell Biology,Karolinska Institute

[2] Department of Medical and Health Sciences,Linkoping University

[3] Department of Cardiovascular Sciences,University of Leicester and NIHR Leicester Cardiovascular Biomedical Research Unit,Glenfield

来源：

Chinese Journal of Cancer | 2016年 / 35卷 / 02期

关键词：

Angiogenesis; Cancer therapy; Anti-angiogenesis; Vascular endothelial growth factor; Biomarker;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

摘要：

In human patients,drugs that block tumor vessel growth are widely used to treat a variety of cancer types.Many rigorous phase 3 clinical trials have demonstrated significant survival benefits;however,the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients.Currently,it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients.In this article,we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.

引用

页码：66 / 74

页数：9

共 32 条

[1] Vasculogenic mimicry:a novel target for glioma therapy[J]. Yin-Sheng Chen,Zhong-Ping Chen.Chinese Journal of Cancer. 2014(02)
[2] The VEGF signaling pathway in cancer: the road ahead[J]. Steven A. Stacker,Marc G. Achen.Chinese Journal of Cancer. 2013(06)
[3] Biomarkers for Systemic Therapy in Ovarian Cancer
Penzvalto, Zsofia
Surowiak, Pawel
Gyorffy, Balazs
[J]. CURRENT CANCER DRUG TARGETS, 2014, 14 (03) : 259 - 273
[4] Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Motzer, Robert J.
Hutson, Thomas E.
McCann, Lauren
Deen, Keith
Choueiri, Toni K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (18): : 1769 - 1770
[5] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial[J] . Edward B Garon,Tudor-Eliade Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N Syrigos,Tuncay Goksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey V Orlov,Conrad R Lewanski,Michael Thomas,Paolo Bidoli,Shaker Da
[6] Molecular Markers to Predict Response to Therapy
Garcia-Donas, Jesus
Rodriguez-Antona, Cristina
Jonasch, Eric
[J]. SEMINARS IN ONCOLOGY, 2013, 40 (04) : 444 - 458
[7] Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues[J] . Yunlong Yang,Yin Zhang,Ziquan Cao,Hong Ji,Xiaojuan Yang,Hideki Iwamoto,Eric Wahlberg,Toste L?nne,Baocun Sun,Yihai Cao.Proceedings of the National Academy of Sciences . 2013 (29)
[8] Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial[J] . Ian F Tannock,Karim Fizazi,Sergey Ivanov,Camilla Thellenberg Karlsson,Aude Fléchon,Iwona Skoneczna,Francisco Orlandi,Gwenaelle Gravis,Vsevolod Matveev,Sevil Bavbek,Thierry Gil,Luciano Viana,Osvaldo Arén,Oleg Karyakin,Tony Elliott,Alison Birtle,Emmanuelle Magherini,Laurence Hatteville,Daniel Petryl
[9] Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients
Tahover, Esther
Uziely, Beatrice
Salah, Azzam
Temper, Mark
Peretz, Tamar
Hubert, Ayala
[J]. MEDICAL ONCOLOGY, 2013, 30 (01)
[10] Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature[J] . Giuseppe Lombardi,Fable Zustovich,Patrizia Farina,Pasquale Fiduccia,Alessandro Della Puppa,Valentina Polo,Roberta Bertorelle,Marina P. Gardiman,Alberto Banzato,Pietro Ciccarino,Luca Denaro,Vittorina Zagonel.Anti-Cancer Drugs . 2013 (1)

← 1 2 3 4 →